



**Seminari del Venerdì del  
Gruppo di Ricerca Geriatrica**

*Recenti acquisizioni in geriatria*

30 dicembre 2005

# **L'ipotiroidismo**

(subclinico)

**Ignazio Di Fazio**


Almost 4 decades ago, Basteine and colleagues used the term *subclinical hypothyroidism* to describe, for the first time, a group of clinically euthyroid individuals with circulating antithyroid antibodies, low normal plasma protein-bound iodine levels, and, using a mouse bioassay, elevated serum thyrotropin levels. Evered and colleagues subsequently described a similar group of asymptomatic individuals in whom *“conventional tests of thyroid function showed nothing abnormal . . . but they were all found to have a raised serum thyrotropin concentration.”*

They also used subclinical hypothyroidism to describe this constellation of clinical and laboratory data. Since then, **hundreds** of articles have been published on this topic, **but physicians are no closer to understanding whether this mild, usually asymptomatic form of hypothyroidism presents a clinical risk, requiring screening for detection and thyroid hormone treatment, or whether screening and therapy are unnecessary and possibly even counterproductive.**

# **Cenni di fisiologia**

# Biosintesi degli ormoni Tiroidei

Nei Tireociti lo ione ioduro ( $I^-$ ) circolante viene captato contro gradiente elettrochimico mediante la pompa dello iodio, con energia fornita da un sistema ATPasico  $Na^+/K^+$  dipendente. La tireoglobulina (Tg), una glicoproteina presente nel lume follicolare della ghiandola, è in grado di legare  $I_2$  ai suoi residui tirosinici per formare i due precursori inattivi, la monoiodotirosina (MIT) e la diiodotirosina (DIT). I processi di ossidazione e organificazione dello iodio avvengono sulla Tg e sono catalizzati dall'enzima perossidasi tiroidea (TPO): dalla condensazione di due molecole di DIT si forma la T4, mentre dall'unione di una molecola di DIT e una di MIT si forma la T3. Infine, in seguito alla proteolisi della Tg, si ha la liberazione di T3 e T4 e la loro secrezione in circolo.





# Effetti “regolativi” degli ormoni tiroidei

- ✓ Sul consumo di  $O_2$  e termogenesi
- ✓ Sulla risposta ventilatoria ed ipossia ed ipercupemia
- ✓ Sulla produzione di eritropoietina
- ✓ Sul turn-over osseo (formazione – riassorbimento)
- ✓ Sui muscoli scheletrici: regola la velocità di rilassamento

**muscolare.** *Il riflessogramma Achilleo misura i tempi di contrazione e rilassamento muscolare dopo stimolazione del tendine di Achille, ed è prolungato nella fase di rilassamento nell'ipotiroidismo.*

# Thyroid function tests in the elderly

- TSH tends to decline slightly with age, but remains in normal range
- Free  $T_4$  remains constant with age
  - There is decreased clearance of thyroxine with age
  - Decreased thyroxine secretion (60 mcg/day compared to 80 mcg/d in younger subjects)
- $T_3$ - slight decline with age, but usually remains in normal range

# L'ipotiroidismo

# Hypothyroidism in the elderly and clinical features

- Prevalence in U.S. population is 5-10%.
- More common in women than men
- Common causes
  - *Autoimmune thyroiditis (Hashimoto's) is most common cause*
  - *Post-treatment of hyperthyroidism*
  - *Drug-induced: amiodarone, radiographic contrast agents, iodine-containing cough syrups, lithium*
- Often lack classic features, or are attributed to old age, e.g. dry skin, constipation, cold intolerance (seen in about 25% of cases)
- Common features in elderly- change in cognitive function, apathy, depression, CHF, carpal tunnel syndrome, arthritis, paresthesias
- Lab findings: anemia, elevated cholesterol, increased CK


# Subclinical hypothyroidism

- Earliest stage of thyroid dysfunction
- Defined as elevated TSH ( $> 4.5$  mIU/L) with normal free T4
- The most common form of thyroid dysfunction in the elderly
- The prevalence of subclinical hypothyroidism in patients older than 65 years varies from 12% to 15%
- Subclinical hypothyroidism is most often detected in older women, in whom the prevalence may be as high as 20%, 75% of those have TSH between 4.5-10mIU/l
- Progression to overt hypothyroidism is higher in elderly and patients with elevated anti-thyroid antibodies


# TSH as a Pharmacodynamic Marker?

- Pituitary Glycoprotein Hormone
- Controls Thyroid Gland Growth and Function
- TSH Production and Secretion Very Sensitive to Circulating Thyroid Hormones
- TSH Secretion is Pulsatile and Circadian
  - Mean Pulse Frequency = 7-13 Pulses/24 hrs
  - Mean Pulse Amplitude = 2.5 mU/L
    - Mean Daytime = 1.5-2.0 mU/L
    - Mean Nighttime = 3.0-4.0 mU/L
- TSH is the most sensitive measure of Thyroid Hormone Action
- Normal Thyroid Hormone Levels are not accurate measures of Normal Thyroid Hormone Action
- The Toxicities of Excessive or Deficient Thyroid Hormone Levels are now defined by TSH Levels, not by Thyroid Hormone Levels

# Thyroid Failure




**In the Past**, thyroxine toxicity defined by clinical presentation  
T4 and TSH levels



**Graves'  
Thyroid Storm**

**Overt Hypothyroidism  
Myxedema Coma**

# Currently, Thyroxine Toxicity Defined Only By TSH Level



## Subclinical Hyperthyroidism

Bone Loss

Fractures

Myocardial Dysfunction

Cardiac Arrhythmias

Death

## Subclinical Hypothyroidism

Increased Lipids

Abnormal Vascular Function

Atherosclerosis, MI

Death

Thyroid Cancer

# **Screening** **& trattamento farmacologico**

# Recommendations of Eight Organizations Regarding Screening of Asymptomatic Adults for Thyroid Dysfunction

**TABLE 1. RECOMMENDATIONS OF EIGHT ORGANIZATIONS REGARDING SCREENING OF ASYMPTOMATIC ADULTS FOR THYROID DYSFUNCTION.**

ORGANIZATION	SCREENING RECOMMENDATIONS
American Thyroid Association <sup>5</sup>	Women and men >35 yr of age should be screened every 5 yr
American Association of Clinical Endocrinologists <sup>6</sup>	Older patients, especially women, should be screened
College of American Pathologists <sup>7</sup>	Women $\geq$ 50 yr of age should be screened "if they seek medical care"; all geriatric patients should be screened on admission to the hospital and at least every 5 yr
American Academy of Family Physicians <sup>8</sup>	Patients $\geq$ 60 yr of age should be screened
American College of Obstetrics and Gynecology <sup>9</sup>	Women in "high-risk groups" (those with autoimmune disease or a strong family history of thyroid disease) should be screened starting at 19 yr of age
American College of Physicians <sup>10</sup>	Women >50 yr of age with an incidental finding suggestive of symptomatic thyroid disease should be evaluated
U.S. Preventive Services Task Force <sup>11</sup>	Insufficient evidence for or against screening
Royal College of Physicians <sup>12</sup>	Screening of the healthy adult population unjustified

# Current Controversies in Endocrinology: Screening of Asymptomatic Elderly for Subclinical Hypothyroidism

*Nina J. Karlin, MD, Nancy Weintraub, MD, and Inder J. Chopra, MD, MACP*

(J Am Med Dir Assoc 2004; 5: 333–336) |

Several issues concerning treatment of subclinical hypothyroidism remain unresolved.

Most agree that a trial of levothyroxine **treatment should be considered in symptomatic patients with positive antithyroid antibodies, high LDL cholesterol, goiter, or repeated serum TSH levels greater than 10 mIU/L.**

**More longitudinal studies** are needed to fully comprehend the consequences of untreated subclinical hypothyroidism on symptoms, atherosclerosis, and overall quality of life, and **how levothyroxine treatment influences these parameters.**

# Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A Summary of the Evidence for the U.S. Preventive Services Task Force

Mark Helfand, MD, MPH

*Ann Intern Med.* 2004;140:128-141.

An elevated TSH level—even a mildly elevated one—is a risk factor for later development of overt hypothyroidism.

**Early treatment would prevent this progression**, but the balance of benefits and harms is unclear.

Other potential harms of subclinical thyroid dysfunction are not well established.


Data on **osteoporosis, fracture, hyperlipidemia**, and **atherosclerotic** disease are **inconsistent**, and most data come from patients who take L-thyroxine or have clinically evident thyroid disease.

Not surprisingly, experts give conflicting advice about the treatment of subclinical hypothyroidism.


Good evidence shows that **L-thyroxine reduces symptoms** (but not lipid levels) in patients who have a markedly elevated TSH level (**>10** mU/L) following surgery or radioiodine treatment.

The main gap in the evidence is the **lack of convincing data from controlled trials** that early treatment reduces lipid levels, symptoms, or the risk for cardiovascular disease in patients with mild thyroid dysfunction detected by screening.

# An Algorithm for the Management of Subclinical Hypothyroidism



**Figure 1.** Suggested Approach to Diagnosis and Management of Subclinical Hypothyroidism



# Subclinical Thyroid Disease

## Scientific Review and Guidelines for Diagnosis and Management

**Table 1.** Quality of Evidence on the Strength of Association and Risks/Benefits of Treatment of Subclinical Hypothyroidism

Clinical Condition	Strength of Association		Benefits of Treatment	
	Serum TSH 4.5-10 mIU/L	Serum TSH >10 mIU/L	Serum TSH 4.5-10 mIU/L	Serum TSH >10 mIU/L
Progression to overt hypothyroidism	Good	Good	*	*
Adverse cardiac end points	Insufficient	Insufficient	No evidence	No evidence
Elevations in serum total and LDL cholesterol	Insufficient	Fair	Insufficient	Insufficient
Cardiac dysfunction	†	Insufficient	Insufficient	Insufficient
Systemic hypothyroid symptoms	None	Insufficient	Insufficient	Insufficient
Neuropsychiatric symptoms	None	Insufficient	Insufficient	Insufficient

Abbreviations: LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.

\*Thyroid hormone therapy normalizes serum TSH at any TSH concentration. Overt hypothyroidism occurs earlier in untreated patients with serum TSH >10 mIU/L than in those with serum TSH between 4.5 and 10 mIU/L.


†Data did not distinguish between serum TSH concentrations between 4.5 and 10 mIU/L and >10 mIU/L.

# **Ipotiroidismo subclinico & malattie cardiovascolari**

- To date, **longitudinal community-based studies** of the relationship between the serum TSH level at the time of study entry and the **incidence of CVD** during the follow-up period have been **mostly negative**.
- In the largest and longest study to date, **2.779** randomly selected men and women 18 years or older from the **Whickham area** in England were carefully examined and then followed up for **20 years**. **No association** was noted between the presence of autoimmune thyroid disease at study entry and subsequent death from ischemic heart disease.
- Similarly, in the **Birmingham study** of a community-based cohort of **1.191** men and women 60 years or older, **no association** existed between an elevated serum TSH level on study entry and death from circulatory disease during the **10-year** follow-up period.
- The **Nagasaki** study of **2.550** men and women 40 years or older showed **no association** between SH and incident ischemic heart disease during a 6-year follow-up.
- Finally, in the **Leiden** study of all persons in the population aged **85 years**, an elevated serum TSH level at entry was associated, remarkably, with a **decreased risk of death from cardiovascular disease** during the **4-year follow-up** period.

# Le dimensioni del problema: Ipotiroidismo e Cardiopatia

- Prevalenza nell'adulto: 6 – 8 casi su 1000 (> F, età avanzata, area a carenza iodica)
- In Italia: su 1.047 pazienti ( 42% Maschi e 58% Femmine, età media  $69,7 \pm 10$  anni), nel 4,8% HF è associato a IPOTIROIDISMO.



# Subclinical Hypothyroidism and Atherosclerosis

## The Rotterdam Study

---

Random sample = 1.149 females

Age =  $69 \pm 7.5$  yrs

TSH Elevated = 10.8% ( $>4$  uU/ml)


End Points = Aortic Atherosclerosis (aortic calcification)  
Myocardial Infarction (MI)

Methods = Cross-sectional

# Subclinical Hypothyroidism and Atherosclerosis

## The Rotterdam Study

---



\*Adjusted for age, BP, BMI, smoking, lipids

Hak AE et al *Annals Int Med*, 2000


# “Minimally” Elevated TSH

## CV Disease + Mortality

### Japanese Study

- 2550 subjects
- 10.2% TSH > 5
- 240/257 (96%) TSH 5-10
- In patients with TSH 5-10:
  - Overall OR 2.7
  - Men OR 4.5
  - Women OR 1.7
  - INDEPENDENT OF CVD Risk Factor


Imaizumi et al. *JCEM*. 2004.



# Minimally Elevated TSH and Lipids

---

- 45 Subclinical Hypo Patients  
TSH = 6.3 uU/ml
- 32 matched controls  
TSH = 1.2  
(gender, age, BMI)
- No obesity, smokers, DM.
- Blinded RCT




# Sub-Clinical Hypothyroidism and Increased Carotid Artery Intimal Media Thickness

---

- **45 SubClinical Hypothyroid Patients**
  - 78% with TSH <10
- **32 matched euthyroid controls (gender, age, BMI)**
- **No obesity, smokers, DM.**
- **Double Blind RCT**

**Carotid Artery IMT by US as  
a marker of early atherosclerosis**



# Effects of Subclinical Thyroid Dysfunction on the Heart

Bernadette Biondi, MD; Emiliano A. Palmieri, MD; Gaetano Lombardi, MD; and Serafino Fazio, MD

**Background:** Mounting evidence indicates that subclinical thyroid dysfunction has important clinical effects and prognostic implications, supporting the view that it is not a compensated biochemical change *sensu strictu*.

**Purpose:** To review clinical information on the effects of subclinical thyroid dysfunction on the heart.

**Data Sources:** English-language articles identified from files and a MEDLINE search (1970–September 2001), references of relevant articles, textbooks, and meeting abstracts.

**Study Selection:** Reports on the effects of subclinical hypothyroidism and subclinical hyperthyroidism on the cardiovascular system in humans.

**Data Extraction:** Data on cardiac structure and performance, arrhythmias, and risk for coronary artery disease were independently assessed by all authors and summarized.

**Data Synthesis:** Subclinical hypothyroidism is associated with

impaired left ventricular diastolic function at rest, systolic dysfunction on effort, and enhanced risk for atherosclerosis and myocardial infarction. Subclinical hyperthyroidism is associated with increased heart rate, atrial arrhythmias, increased left ventricular mass with marginal concentric remodeling, impaired ventricular relaxation, reduced exercise performance, and increased risk for cardiovascular death. All abnormalities were reversed by restoration of euthyroidism (subclinical hypothyroidism) or were blunted by  $\beta$ -blockade and tailoring of the L-thyroxine dose (subclinical hyperthyroidism).

**Conclusion:** The heart responds to the minimal but persistent changes in circulating thyroid hormone levels typical of subclinical thyroid dysfunction. Thus, the condition is not a compensated biochemical change *sensu strictu*, and timely treatment should be considered in an attempt to avoid adverse cardiovascular effects.


*Ann Intern Med.* 2002;137:904-914.

[www.annals.org](http://www.annals.org)

For author affiliations, see end of text.

# Subclinical Thyroid Dysfunction as a Risk Factor for Cardiovascular Disease

John P. Walsh, MBBS, PhD; Alexandra P. Bremner, PhD; Max K. Bulsara, MSc; Peter O'Leary, PhD; Peter J. Leedman, MBBS, PhD; Peter Feddema, BSc; Valdo Michelangeli, PhD



**Figure.** Kaplan-Meier plots for survival free of coronary heart disease events (fatal or nonfatal) in subjects without coronary heart disease at baseline.

**2.108 patients** (>50 years old)

**Cross-sectional analysis,** S-HT (n=119) had a significantly **higher prevalence of CHD** than euthyroid (n=1906) (OR 1.8).

**Longitudinal analysis (20 y.)** S-HT (n=101), **21 cardiovascular deaths** observed (HR, 1.5) and **33 coronary heart disease** (HR, 1.7).


**Table 4. Hazard Ratios for Coronary Heart Disease Events (Fatal and Nonfatal) in the Longitudinal Analysis of Subjects Free of Coronary Heart Disease at Baseline\***

Variable	Subclinical Hyperthyroid Group (n = 37)	Euthyroid Group (n = 1752)	Subclinical Hypothyroid Group (n = 101)	Subclinical Hypothyroid Group	
				Thyrotropin ≤10.0 mIU/L (n = 77)	Thyrotropin >10.0 mIU/L (n = 24)
Coronary heart disease events					
Observed	5	229	33	23	10
Expected	6.0	245.0	14.7	10.8	3.8
Hazard ratio (95% confidence interval)					
Age and sex adjusted	1.0 (0.4-2.5)	1.0	1.7 (1.2-2.4)	1.5 (1.0-2.3)	2.2 (1.2-4.2)
P value	.79	...	<.01	.06	.01
Further adjusted†	1.3 (0.6-3.3)	1.0	1.8 (1.2-2.7)	1.6 (1.0-2.6)	2.6 (1.3-5.3)
P value	.51	...	<.01	.04	<.01

The increased risk of coronary heart disease events remained significant after further adjustment for standard cardiovascular risk factors. **Subclinical hypothyroidism may be an independent risk factor for coronary heart disease.**

# Subclinical Hypothyroidism and the Risk of Heart Failure, Other Cardiovascular Events, and Death

Nicolas Rodondi, MD, MAS; Anne B. Newman, MD, MPH; Eric Vittinghoff, PhD; Nathalie de Rekeneire, MD; Suzanne Satterfield, MD; Tamara B. Harris, MS, MD; Douglas C. Bauer, MD



**Figure.** Cumulative congestive heart failure (CHF) events in older subjects according to thyrotropin (TSH) levels. The rate of CHF events increased with higher TSH levels ( $P=.03$  for trend). Participants with a TSH level of 7.0 mIU/L or greater had a higher rate of CHF events compared with euthyroid participants ( $P=.006$ ); this was not the case for those with a TSH level between 4.5 and 6.9 mIU/L.

**3,075** patients, aged 70 to 79 at enrollment, follow-up 4 years.

Subclinical hypothyroidism was present in 12.4% of the participants.

**CHF events** occurred more frequently among those with a TSH level of **>7.0** mIU/L, but not among those with TSH levels between 4.5 and 6.9 mIU/L.

In multivariate analyses, the **risk of CHF** was higher among those with high TSH levels (TSH of 7.0-9.9 mIU/L: **HR, 2.58** and TSH of 10.0 mIU/L **HR, 3.26**).

Subclinical hypothyroidism is associated with an increased risk of CHF among older adults with a TSH level of 7.0 mIU/L or greater, but **not with other cardiovascular events and mortality**.

# **Ipotiroidismo subclinico & stato mentale**

- Several intervention trials have suggested that S-HT is associated with **memory deficits** in younger individuals that are **reversible** to some extent with thyroid hormone therapy.
- Cross-sectional studies of **geriatric populations** have **not shown differences** in **cognitive function** between euthyroid individuals and those with mild hypothyroidism.
- In cross-sectional studies focusing on **depression** in geriatric populations, some found **a possible relationship** between depression and **elevated TSH** levels, while others did not.

# Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment

Bono G, Fancellu R, Blandini F, Santoro G, Mauri M. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment.

Acta Neurol Scand 2004; 110: 59-66. © Blackwell Munksgaard 2004.

**Objectives** – While clinical hypothyroidism is associated with frank neuropsychological and affective alterations and is considered one of the causes of reversible dementia, the occurrence of these alterations and their treatment in mild hypothyroidism (MH) remains a controversial issue. Our aim was therefore to evaluate cognitive and psychological functions in a selected population of recently-diagnosed MH patients with minor subjective symptoms. **Materials and methods** – Thirty-six MH women (mean age  $51.9 \pm 13.5$  years) were observed after a careful assessment had excluded subjects with neurological, psychiatric and/or somatic disorders, or confounding conditions. The subjects were evaluated for thyroid function and tested with an extensive battery of neuropsychological tests and psychological rating scales, in basal conditions and after 6 months of L-thyroxine treatment. **Results** – Baseline neuropsychological performance was within the normal range, while an age-dependent reduction was found in attentive function. After L-thyroxine treatment, an increase in serum FT4 was detected in parallel with thyroid stimulating hormone (TSH) reduction. Verbal fluency and depression scores showed a slight improvement. A positive correlation was found between TSH reduction and improved mood scores. **Conclusion** – From the analysis of the results, treatment of asymptomatic MH would seem advisable in order to re-set hormonal levels and, particularly in older subjects, to protect the brain against the potential risk of cognitive and affective dysfunctions.

**G. Bono<sup>1</sup>, R. Fancellu<sup>1</sup>,  
F. Blandini<sup>2</sup>, G. Santoro<sup>3</sup>,  
M. Mauri<sup>1</sup>**

<sup>1</sup>Unit of Neurology, Ospedale di Circolo, University of Insubria, Varese, Italy; <sup>2</sup>IRCCS C. Mondino Institute of Neurology, Pavia, Italy; <sup>3</sup>Department of Internal Medicine, Ospedale di Circolo, University of Insubria, Varese, Italy

**Key words:** depression; L-thyroxine; neuropsychological functions; reversible dementia; subclinical hypothyroidism; thyroid hormones; TSH

Giorgio Bono, Unit of Neurology, Ospedale di Circolo, University of Insubria, 57 Viale Borri, 21100 Varese, Italy  
Tel: +39-0332-278427  
Fax: +39-0332-261440  
e-mail: neurova@tin.it

Accepted for publication October 20, 2003

# **Ipotiroidismo subclinico & stato funzionale**

# Thyroid Status, Disability and Cognitive Function, and Survival in Old Age

Jacobijn Gussekloo, MD, PhD

Eric van Exel, MD, PhD

Anton J. M. de Craen, PhD

Arend E. Meinders, MD, PhD

Marijke Frölich, PhD

Rudi G. J. Westendorp, MD, PhD

**T**HYROID DYSFUNCTION IN ELDERLY individuals often occurs unnoticed. Hence, screening for both hypothyroidism and hyperthyroidism has been recommended, especially in old age.<sup>1,2</sup> Apart from finding individuals with previously unrecognized overt hypothyroidism and hyperthyroidism, screening will also reveal persons with subclinical thyroid dysfunction. These individuals have abnormal plasma levels of thyrotropin combined with normal plasma levels of free thyroxine.

Subclinical thyroid dysfunction has been associated with various negative clinical outcomes and an increased risk of overt thyroid dysfunction. Two recent literature reviews of subclinical thy-

**Context** Despite the equivocal outcomes of randomized controlled trials, general clinical opinion favors screening and treatment of elderly individuals with subclinical thyroid disorders.

**Objectives** To determine whether subclinical thyroid dysfunction should be treated in old age and the long-term impact of thyroid dysfunction on performance and survival in old age.

**Design, Setting, and Participants** A prospective, observational, population-based follow-up study within the Leiden 85-Plus Study of 87% of a 2-year birth cohort (1912-1914) in the municipality of Leiden, the Netherlands. A total of 599 participants were followed up from age 85 years through age 89 years (mean [SD] follow-up, 3.7 [1.4] years).

**Main Outcome Measures** Complete thyroid status at baseline; disability in daily life, depressive symptoms, cognitive function, and mortality from age 85 years through 89 years.

**Results** Plasma levels of thyrotropin and free thyroxine were not associated with disability in daily life, depressive symptoms, and cognitive impairment at baseline or during follow-up. Increasing levels of thyrotropin were associated with a lower mortality rate that remained after adjustments were made for baseline disability and health status. The hazard ratio (HR) for mortality per SD increase of 2.71 mIU/L of thyrotropin was 0.77 (95% confidence interval [CI], 0.63-0.94;  $P = .009$ ). The HR for mortality per SD increase of 0.21 ng/dL (2.67 pmol/L) of free thyroxine increased 1.16-fold (95% CI, 1.04-1.30;  $P = .009$ ).

**Conclusions** In the general population of the oldest old, elderly individuals with abnormally high levels of thyrotropin do not experience adverse effects and may have a prolonged life span. However, evidence for not treating elderly individuals can only come from a well-designed, randomized placebo-controlled clinical trial.

**Table 2.** Baseline Characteristics for Clinical Strata of Thyroid Function\*

	Abnormally Low Thyrotropin†			Abnormally High Thyrotropin§		P Value for Trend
	Overt Hyperthyroidism	Subclinical Hyperthyroidism	Normal Level of Thyrotropin‡	Subclinical Hypothyroidism	Overt Hypothyroidism	
No. of participants	2	17	472	30	37	
Body mass index	21.5 (2.3)	25.6 (5.1)	27.1 (4.5)	27.7 (3.8)	28.3 (4.8)	.02
Total cholesterol, mmol/L	5.6 (0.7)	5.4 (1.5)	5.7 (1.1)	6.4 (1.3)	5.8 (1.0)	.04
Triglycerides, mmol/L	1.3 (0.5)	1.7 (1.1)	1.5 (0.7)	1.9 (1.1)	1.9 (1.2)	.004
C-reactive protein, mg/L	4.8 (2.0)	5.4 (2.6)	4.8 (2.9)	7.4 (2.6)	4.4 (7.9)	.77

SI conversion factors: To convert total cholesterol, divide by 0.0259; triglycerides, divide by 0.0113.

\*Data are presented as mean (SD) except for C-reactive protein, which is geometric mean (SD).

†Defined as below 0.3 mIU/L.

‡Defined as 0.3 to 4.8 mIU/L.

§Defined as above 4.8 mIU/L.

||Differences in mean baseline characteristics were analyzed with analysis of variance test for linearity.

At the start of the follow-up period, individuals who had elevated serum thyrotropin levels at baseline had comparable activity, cognitive function, and depressive feelings compared with individuals with normal thyroid function. Thus, there was no evidence that overt or subclinical hypothyroidism affected elderly individuals' performance status or mood.

After 3 years, none of the individuals with subclinical hypothyroidism had progressed to overt hypothyroidism.

During the annual follow-up examination, those participants with increased serum thyrotropin levels actually had a similar or less rapid decline in specific disability measures compared with individuals with normal thyroid function.

In this prospective observational study of a population-based cohort of individuals aged 85 years, no consistent associations were found between thyroid status and ADLs, depressive symptoms, and cognitive performance, neither in the cross-sectional nor in the prospective analyses.

Gusselkoo, 2004

In summary, it appears that neither subclinical hypothyroidism nor overt hypothyroidism is a cause of decline in performance, altered cognition or mood, or long-term survival in the oldest old.

Cooper, 2004

# **Ipotiroidismo subclinico & outcome funzionale**

**Table 1. Demographic characteristics, mental and functional status on admission**

	<b>Normal thyroid function</b>	<b>S-HT</b>	<b>p</b>	
	<b>(n=1.073)</b>	<b>(n=71)</b>		
	<i>Mean ± S.D.</i>			
<b>Demographic</b>	<b>Age (years)</b>	78.1±7.3	76.4±7.4	.000
	<b>Female (%)</b>	73.3	66.2	.000
<b>Mental &amp; Functional Status</b>	<b>MMSE</b>	22.0±6.1	21.5±5.7	n.s.
	<b>GDS</b>	5.8±3.6	6.1±3.7	n.s.
	<b>BARTHEL INDEX (last week)</b>	62.6±28.7	57.3±30.6	n.s.

**Table 2. Comorbidity, nutritional status and biomarkers of inflammation**

		<b>Normal thyroid function</b>	<b>S-HT</b>	<b>p</b>
		<b>(n=1.073)</b>	<b>(n=71)</b>	
		<i>Mean ± S.D.</i>		
<b>Comorbidity</b>	<b>Burden od Diseases</b>	10.3±4.2	11.8±3.6	.005
	<b>Drugs</b> (number on adm.)	5.5±2.8	6.1±2.6	.002
<b>Nutritional status &amp; Inflammatory burden</b>	<b>BMI (Kg/m<sup>2</sup>)</b>	26.6±5.9	27.9±4.9	n.s.
	<b>Total cholesterol (mg/dl)</b>	179.6±44.4	186.2±42.9	n.s.
	<b>Albumin (g/l)</b>	3.5±.4	3.4±.4	n.s.
	<b>ESR (mm/h)</b>	28.6±24.5	27.3±21.4	n.s.
	<b>C-RP (U/dl)</b>	2.1±5.1	2.1±4.5	n.s.

### **Tabella 3. Functional Outcome**

	<b>Normal thyroid function</b>	<b>S-HT</b>	<b>p</b>
	<b>(n=1.073)</b>	<b>(n=71)</b>	
<b>Balance and gait (Tinetti score)</b>			
		<i>Mean ± S.D.</i>	
<b>On admission</b>	14.0±8.9	12.6±9.4	n.s.
<b>On discharge</b>	19.2±7.9	16.4±8.7	.005
<b>Change admission to discharge</b>	5.2±5.5	3.8±4.1	.005

**Table 4. Determinants of Functional Recovery**

**Dependent variable**  
**Delta-Tinetti**

---

**Adjusted R<sup>2</sup>= .37    p<.005**

<b>Variables</b>	<b>B</b>	<b>95% C.I.</b>	<b>Sig.</b>
Subclinical hypothyroidism	-2.2	- (3.3 – 1)	.001
Age	-.07	- (.11 – .03)	.000
MMSE	.13	(.06 – .20)	.000
Depressive symptoms	-.11	- (.20 – .03)	.001
Tinetti score (on admission)	-.39	- (.4 – 36)	.000
Stroke	-.51	- (.3 – 13)	.000

---

*Values were computed in multiple linear regression model adjusted for following diseases (heart diseases, diabetes and atrial fibrillation), and potential predictors as total cholesterol, albumin and c-reactive protein.*

# Presentazione “**subclinica**” & outcome

L'esempio del diabete

# Impaired fasting glucose concentration in non diabetic patients with ischemic heart disease: a marker for a worse prognosis

*EZ Fisman, M Motro, A Tenebaum, V Boyko, L Mandelzweig, S Behar*  
American Heart Journal, 2001

- 11,853 subjects (>45 years) with documented CHD
- 3 groups:
  - non diabetic,
  - **IFG** (glucose 110-125mg/dl),
  - undiagnosed diabetic patients
- Follow-up: from 6 to 9 years
- **IFG**: consistent predictor of increased all cause (HR 1.4) and ischemic heart disease mortality (HR 1.3)

# Impaired Fasting Glucose and Cardiovascular Outcomes in Postmenopausal Women with Coronary Artery Disease

Alka M. Kanaya, MD; David Herrington, MD, MHS; Eric Vittinghoff, PhD; Feng Lin, MS; Vera Bittner, MD, MSPH; Jane A. Cauley, DrPH; Stephen Hulley, MD; and Elizabeth Barrett-Connor, MD

## ***Commento (1)***

- I nostri dati dimostrano che nei pazienti con ipotiroidismo sub-clinico è maggiore il rischio di scarso recupero funzionale dopo un periodo di riabilitazione motoria.
- Tale rischio è indipendente dalla comorbilità.
- In apparente contraddizione con i nostri dati, Gussekloo e collaboratori hanno recentemente dimostrato l'assenza di un legame tra S-HT e outcome quali stato funzionale, stato cognitivo e sintomi depressivi, a distanza di quattro anni.

## **Commento (2)**

- Dal nostro punto di vista, l'effetto clinico dell'S-HT sullo stato funzionale potrebbe evidenziarsi in corso di aumentata richiesta energetica, come avviene nel breve periodo della riabilitazione motoria. Nel lungo periodo, invece, la relazione esistente tra tiroide e stato funzionale, potrebbe essere mascherata dall'instaurarsi di un nuovo equilibrio funzionale.
- L'S-HT influenzerebbe l'outcome funzionale, attraverso un ridotto "rate metabolico", la cui importanza appare critica durante la fase di riabilitazione.

# Conclusioni

- L'S-HT è molto probabilmente associato ad eventi cardiovascolari, probabilmente mediati dalle alterazioni del metabolismo lipidico.
- Sono insufficienti i dati della letteratura relativamente all' associazione tra S-HT e funzioni cognitive, tono dell'umore, perdita dell'autosufficienza e sopravvivenza.
- Il livello di TSH sierico sembra comunque essere alla base delle alterazioni fisiopatologiche tipiche dell'ipotiroidismo (sia overt che subclinico)
- Le evidenze esistenti, sembrano accreditare la necessità di effettuare screening della funzione tiroidea nei pazienti anziani asintomatici
- Ad oggi non esistono sufficienti evidenze riguardo all'efficacia del trattamento dell'ipotiroidismo subclinico, *ma potrebbe essere ragionevole il trattamento nei pazienti anziani con patologia cardiovascolare?*
- I nostri dati, in linea con le evidenze relative al ruolo del IFG rispetto all'outcome cardiovascolare, aprono delle prospettive nel rapporto tra malattie a presentazione "subclinica" ed outcome nell'anziano
- Lo scarso recupero funzionale nei pazienti anziani potrebbe rappresentare un "sintomo geriatrico" dell'S-HT che non dovrebbe quindi essere considerato solo una diagnosi di laboratorio.

*The young man knows the rules, but  
the old man knows the exceptions.*

*Oliver Wendell Holmes*